If your email program has trouble displaying this email, view as a webpage. Advancing FDA's Mission by Targeting Key Areas for Regulatory Science Investment and Innovation We live in an era of rapidly changing technological advancements that enable science to evolve at an unprecedented pace. At the U.S. Food and Drug Administration, we rely on our scientific and technical experts to make sound, science- and evidence-based regulatory decisions to protect and promote public health. As we march forward, the FDA aims to deepen its connections among external stakeholders and experts, and our own scientists. In this post, you will learn about the way we are reshaping our regulatory science programs to facilitate these interactions. The FDA's Strategic Plan for Advancing Regulatory Science identified nine science priority areas where it considered new or enhanced engagement would be essential to the continued success of the FDA's public health and regulatory mission. Over the past decade, the Office of the Chief Scientist has been integral to executing this plan. Its Office of Regulatory Science and Innovation has launched and supported cross-agency collaborative programs aligned with these priorities. The Intramural Research Grants Program and Scientific Working Groups such as the Alternative Methods Working Group are two examples.

Stay Connected with U.S. Food and Drug Administration:

SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA